Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells

Gastroenterology

Volumn 119, Issue 2, 2000, Pages 479-492

  Failli, Paola ^a   DeFranco, Raffaella M S ^a   Caligiuri, Alessandra ^a   Gentilini, Alessandra ^a   Romanelli, Roberto Giulio ^a   Marra, Fabio ^a   Batignani, Giacomo ^b   Guerra, Cristina Tosti ^a   Laffi, Giacomo ^a   Gentilini, Paolo ^a   Pinzani, Massimo ^a  

^a Dipartimento di Medicina Interna   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE DONOR; NITRO DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; VASODILATOR AGENT;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIVER FIBROSIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; STELLATE CELL; VASODILATATION;

EID: 0033868025     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.9354     Document Type: Article

References (68)

1. Nitrovasodilators and portal hypertension
2. Organic nitrates in portal hypertension
3. Pharmacological treatment of portal hypertension: Present and future
4. Long-term hemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension
5. Propanolol compared with propanolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: A randomized controlled study
6. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients
7. Significance of septal fibrosis for disturbance of hepatic circulation
8. Fat-storing cells as liver-specific pericytes: Spatial dynamics of agonist-stimulated intracellular calcium transients
9. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo
10. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin and nitric oxide
11. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies
12. Novel insights into the biology and physiology of the Ito cell
13. Endothelin-1 is overexpressed in cirrhotic liver and exerts multiple effects on activated human hepatic stellate cells
14. Expression of the thrombin receptor in human liver. Upregulation during acute and chronic disease
15. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility
16. Nitric oxide modulates hepatic vascular tone in normal rat liver
17. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids
18. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension
19. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats
20. Nitric oxide in liver injury
21. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured liver fat-storing cells
22. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's action on hepatic stellate cells
23. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis
24. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells. Role of nitric oxide
25. Nitric oxide-generating compounds inhibit total protein synthesis in cultured vascular smooth muscle cells
26. Smooth muscle α-actin expression in rat hepatic stellate cell is regulated by nitric oxide and cGMP production
27. Nitric-oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
28. Inhibition or rat mesangial cell mitogenesis by nitric oxide-generating vasodilators
29. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP
30. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells
31. Regulation of extracellular matrix synthesis by transforming growth factor β1 in human fat-storing cells
32. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells
33. Involvement of phosphatidylinositol 3-kinase in action of extracellular signal-regulated kinase by PDGF in hepatic stellate cells
34. The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx
35. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction
36. Transforming growth factor-β1 regulates platelet-derived growth factor receptor β subunit in human liver fat-storing cells
37. Effect of some cyclooxygenase inhibitors on the increase in guanosine 3':5'-cyclic monophosphate induced by NO-donors in human whole platelets
38. Focal adhesion kinase and phospholipase Cγ involvement in cell adhesion and migration of human hepatic stellate cells
39. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in non-azotemic cirrhotic patients with ascites
40. Mechanism of vascular smooth muscle relaxation by organic nitrites, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates
41. Cyclic GMP synthesis and function
42. Receptor guanylyl cyclases
43. Soluble guanylate cyclase: The forgotten sibling
44. Intracellular cyclic GMP receptor proteins
45. Properties of a cGMP-dependent monomeric protein kinase from bovine aorta
46. 2+ current is regulated by cGMP-dependent protein kinase in mammalian cardiac myocytes
47. Cyclic GMP-dependent protein kinase and smooth muscle relaxation
48. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth cells
49. Activation of p38 mitogen-activated protein kinase by lipopolysaccharide in human neutrophils requires nitric oxide-dependent cGMP accumulation
50. Nitric oxide activates cyclooxygenase enzymes
51. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors
52. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells
53. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells
54. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus
55. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype
56. Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide
57. 2+: A story with a complex past and a promising future
58. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent kinase
59. Protein kinase G is not essential to NO-cGMP modulation of basal tone in rat pulmonary circulation
60. Human soluble guanylate cyclase: Functional expression and revised isoenzyme family
61. Heme-dependent activation of soluble guanylate cyclase by nitric oxide: Regulation of enzyme activity by porphyrins and metalloporphyrins
62. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1β
63. Identification and partial purification of an endogenous inhibitor of soluble guanylyl cyclase from bovine lung
64. Nitric oxide-mediated cyclo-oxygenase activation. A key event in the antiplatelet effects of nitrovasodilators
65. Regulation of prostaglandin production by nitric oxide; an in vivo analysis
66. Regulation of cyclooxygenase enzymes by nitric oxide
67. 2+)-ATPases of the plasma membrane and of the endoplasmic reticulum in smooth muscle cells and their regulation
68. Drugs used for the treatment of myocardial ischemia